Science and Research

Enzymatic Modulation of the Pulmonary Glycocalyx Enhances Susceptibility to Streptococcus pneumoniae

The pulmonary epithelial glycocalyx is rich in glycosaminoglycans such as hyaluronan and heparan sulfate. Despite their presence, the importance of these glycosaminoglycans in bacterial lung infections remains elusive. To address this, we intranasally inoculated mice with Streptococcus pneumoniae in the presence or absence of enzymes targeting pulmonary hyaluronan and heparan sulfate, followed by characterization of subsequent disease pathology, pulmonary inflammation, and lung barrier dysfunction. Enzymatic degradation of hyaluronan and heparan sulfate exacerbated pneumonia in mice, as evidenced by increased disease scores and alveolar neutrophil recruitment. However, targeting epithelial hyaluronan in combination with Streptococcus pneumoniae infection further exacerbated systemic disease, indicated by elevated splenic bacterial load and plasma levels of pro-inflammatory cytokines. In contrast, enzymatic cleavage of heparan sulfate resulted in increased bronchoalveolar bacterial burden, lung damage and pulmonary inflammation in mice infected with Streptococcus pneumoniae. Accordingly, heparinase-treated mice also exhibited disrupted lung barrier integrity as evidenced by higher alveolar edema scores and vascular protein leakage into the airways. This finding was corroborated in a human alveolus-on-a-chip platform, confirming that heparinase treatment also disrupts the human lung barrier during Streptococcus pneumoniae infection. Notably, enzymatic pre-treatment with either hyaluronidase or heparinase also rendered human epithelial cells more sensitive to pneumococcal-induced barrier disruption, as determined by transepithelial electrical resistance measurements, consistent with our findings in murine pneumonia. Taken together, these findings demonstrate the importance of intact hyaluronan and heparan sulfate in limiting pneumococci-induced damage, pulmonary inflammation, and epithelial barrier function and integrity.

  • Goekeri, C.
  • Linke, K. A. K.
  • Hoffmann, K.
  • Lopez-Rodriguez, E.
  • Gluhovic, V.
  • Voß, A.
  • Kunder, S.
  • Zappe, A.
  • Timm, S.
  • Nettesheim, A.
  • Schickinger, S. M. K.
  • Zobel, C. M.
  • Pagel, K.
  • Gruber, A. D.
  • Ochs, M.
  • Witzenrath, M.
  • Nouailles, G.

Keywords

  • CAP, pneumococcal virulence, acute lung injury, glycosaminoglycans, heparan
  • sulfate, hyaluronan
Publication details
DOI: 10.1165/rcmb.2024-0003OC
Journal: Am J Respir Cell Mol Biol
Work Type: Original
Location: Assoziierter Partner
Disease Area: PALI
Partner / Member: BIH
Access-Number: 39042016

DZL Engagements

chevron-down